Bone markers and cardiovascular risk in type 2 diabetes patients.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Zwakenberg, Sabine Rvan der Schouw, Yvonne T
Schalkwijk, Casper G
Spijkerman, Annemieke M W
Beulens, Joline W J
Type
ArticleLanguage
en
Metadata
Show full item recordTitle
Bone markers and cardiovascular risk in type 2 diabetes patients.Published in
Cardiovasc Diabetol 2018; 17(1):45Publiekssamenvatting
Vascular calcifications are associated with a three- to fourfold increased risk of cardiovascular disease (CVD) and are highly prevalent in type 2 diabetes patients. Emerging evidence indicates that vascular calcification is a process of active bone formation regulated by stimulators and inhibitors of calcification. Therefore, this study aimed to evaluate whether six bone markers are associated with CVD risk in patients with type 2 diabetes.PMID
29571288ae974a485f413a2113503eed53cd6c53
10.1186/s12933-018-0691-2
Scopus Count
Collections
Related articles
- Association between bone metabolism regulators and arterial stiffness in type 2 diabetes patients.
- Authors: Sharif S, Bots ML, Schalkwijk C, Stehouwer CDA, Visseren FLJ, Westerink J, SMART study group.
- Issue date: 2018 Dec
- Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
- Authors: Barchetta I, Ceccarelli V, Cimini FA, Bertoccini L, Fraioli A, Alessandri C, Lenzi A, Baroni MG, Cavallo MG
- Issue date: 2019 May
- Plasma advanced glycation end products are associated with incident cardiovascular events in individuals with type 2 diabetes: a case-cohort study with a median follow-up of 10 years (EPIC-NL).
- Authors: Hanssen NM, Beulens JW, van Dieren S, Scheijen JL, van der A DL, Spijkerman AM, van der Schouw YT, Stehouwer CD, Schalkwijk CG
- Issue date: 2015 Jan
- Plasma <i>N</i>-Glycans as Emerging Biomarkers of Cardiometabolic Risk: A Prospective Investigation in the EPIC-Potsdam Cohort Study.
- Authors: Wittenbecher C, Štambuk T, Kuxhaus O, Rudman N, Vučković F, Štambuk J, Schiborn C, Rahelić D, Dietrich S, Gornik O, Perola M, Boeing H, Schulze MB, Lauc G
- Issue date: 2020 Mar
- Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies.
- Authors: Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, Liang L, Salas-Huetos A, Pierce KA, Guasch-Ferré M, Corella D, Ros E, Estruch R, Gómez-Gracia E, Fitó M, Lapetra J, Romaguera D, Alonso-Gómez A, Serra-Majem L, Salas-Salvadó J, Hu FB, Martínez-González MA
- Issue date: 2019 Nov 13